Product Name
PRRT2, siRNA
Full Product Name
PRRT2 siRNA (Human)
Product Synonym Names
Proline-rich transmembrane protein 2; Dispanin subfamily B member 3; DSPB3
Product Gene Name
PRRT2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q7Z6L0
Specificity
PRRT2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human PRRT2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of PRRT2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
PRRT2 sirna
siRNA to inhibit PRRT2 expression using RNA interference
Applications Tested/Suitable for PRRT2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for PRRT2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001243371.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001256442.1
[Other Products]
UniProt Primary Accession #
Q7Z6L0
[Other Products]
UniProt Secondary Accession #
Q8N2N8; Q8NAQ7; Q8ND36; Q96FA8; A8K8M8[Other Products]
UniProt Related Accession #
Q7Z6L0[Other Products]
Molecular Weight
30,653 Da
NCBI Official Full Name
proline-rich transmembrane protein 2 isoform 2
NCBI Official Synonym Full Names
proline-rich transmembrane protein 2
NCBI Official Symbol
PRRT2 [Similar Products]
NCBI Official Synonym Symbols
PKC; EKD1; ICCA; BFIC2; BFIS2; DSPB3; DYT10; FICCA; IFITMD1
[Similar Products]
NCBI Protein Information
proline-rich transmembrane protein 2
UniProt Protein Name
Proline-rich transmembrane protein 2
UniProt Synonym Protein Names
Dispanin subfamily B member 3; DSPB3
Protein Family
Proline-rich transmembrane protein
UniProt Gene Name
PRRT2 [Similar Products]
UniProt Synonym Gene Names
DSPB3 [Similar Products]
UniProt Entry Name
PRRT2_HUMAN
NCBI Summary for PRRT2
This gene encodes a transmembrane protein containing a proline-rich domain in its N-terminal half. Studies in mice suggest that it is predominantly expressed in brain and spinal cord in embryonic and postnatal stages. Mutations in this gene are associated with episodic kinesigenic dyskinesia-1. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2012]
UniProt Comments for PRRT2
PRRT2: Defects in PRRT2 are the cause of episodic kinesigenic dyskinesia type 1 (EKD1). An autosomal dominant neurologic condition characterized by recurrent and brief attacks of abnormal involuntary movements, triggered by sudden voluntary movement. These attacks usually have onset during childhood or early *****hood and can involve dystonic postures, chorea, or athetosis. Disease-causing mutations that produce truncation of the C-terminus of the protein alter subcellular location, from plasma membrane to cytosplasm (PubMed:22101681). Defects in PRRT2 are the cause of convulsions, familial infantile, with paroxysmal choreoathetosis (ICCA). A syndrome characterized by clinical features of benign familial infantile seizures and episodic kinesigenic dyskinesia. Benign familial infantile seizures is a disorder characterized by afebrile seizures occurring during the first year of life, without neurologic sequelae. Paroxysmal choreoathetosis is a disorder of involuntary movements characterized by attacks that occur spontaneously or are induced by a variety of stimuli. Defects in PRRT2 are the cause of seizures, benign familial infantile type 2 (BFIS2). An autosomal dominant disorder in which afebrile seizures occur in clusters during the first year of life, without neurologic sequelae. Belongs to the CD225/Dispanin family. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral; Membrane protein, multi-pass
Chromosomal Location of Human Ortholog: 16p11.2
Cellular Component: integral to membrane; plasma membrane; synapse; cell junction
Biological Process: neuromuscular process controlling posture; response to biotic stimulus
Disease: Episodic Kinesigenic Dyskinesia 1
Research Articles on PRRT2
1. phenotypic spectrum of biallelic mutations
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
